At a glance

What it is

What BPC-157 is and why people ask about it

BPC stands for body protection compound. BPC-157 is a laboratory-made chain of 15 amino acids that copies part of a protein first isolated from human stomach fluid. It is not a hormone your body makes in this form.

People ask about it for tendon, joint and muscle injuries, gut complaints and general recovery. These are the uses promoted online. None is an FDA-approved use, and as the next sections show, none is backed by good human trials.

In animal and cell experiments it has been linked to blood vessel growth, changes in inflammation signals and faster healing of injured tissue. Those findings are a reason to run human trials. They are not a reason to expect the same result in a person.

Evidence

What the human studies actually show

The honest summary is that the evidence is thin. A 2026 systematic review searched for every human study through June 1, 2026 and found only three, with 30 people in total. It rated the certainty of the evidence very low and the study quality poor, and it concluded BPC-157 should not be used in people outside regulated, high-quality trials.

The studies that exist

• Ulcerative colitis. A multicenter, randomized, placebo-controlled study from 2005 enrolled 53 people with mild to moderate disease and gave the peptide as an enema for two weeks. It is available only as a meeting abstract. FDA’s reviewers noted the authors gave limited information on safety monitoring, and the study cannot speak to long-term use.
• Healthy volunteers. Two early phase 1 tolerability studies, also known only from meeting abstracts, gave the peptide as an enema to 24 people. The reports describe no significant adverse events attributed to it. FDA found that it did not appear to be absorbed into the blood by that route.
• Knee pain. A retrospective chart review of people given a joint injection looked back at 16 contacted patients. A review of the sports medicine literature reported that 7 of 12 patients described relief lasting more than six months. A chart review has no placebo group, so it cannot separate the peptide from the natural course of knee pain.
• Bladder pain and a tiny infusion study. A 12-woman pilot for interstitial cystitis and a two-person infusion safety pilot reported no adverse events. Two people cannot establish safety.
• Registered trials. FDA’s search of ClinicalTrials.gov found one phase 1 study in healthy adults in Mexico (NCT02637284), planned for about 42 people. No results were posted and FDA could not find a published report.

Of the animal work, FDA’s review said the toxicology studies were too limited in scope and duration to inform safety for human use. Results vary between people, and trials in different populations are not directly comparable.

Safety

Safety unknowns and who should not use it

FDA’s own review concluded there is insufficient clinical safety information to characterize the safety profile of BPC-157. Its search of the adverse event database found only three reports, all involving injected products. They included injection site redness and swelling, a visit to an emergency room for shortness of breath, and dark skin and gum pigmentation that returned on rechallenge with a product that also contained a second peptide. Three reports in a poorly monitored market tell us little. They do not show the peptide is safe.

Reviewers have also pointed to questions that animal data cannot settle. Peptides can provoke an immune response or clump together. A substance that promotes blood vessel growth raises a theoretical concern in anyone with a cancer history, because tumors depend on new vessels. There is no human data on this either way.

Who should not use it

• Anyone who is pregnant, trying to conceive or breastfeeding. There are no human data.
• Anyone with a current or past cancer, or an unexplained mass under evaluation.
• Children and teenagers.
• Anyone with a history of allergic reactions to peptide or injectable medications.
• Competitive athletes who are drug tested.
• Anyone whose goal is something a better-studied treatment can address first, such as a tendon injury that has not had a proper exam, imaging and rehabilitation.

Quality

Why the source of the product matters

Much of the BPC-157 sold online is labeled for research use only and is not made to pharmaceutical standards. FDA reviewers cataloged many such products. A vial from an unknown seller may contain the wrong amount, a different substance, or contaminants, and nobody inspects it for you.

A prescription from a physician, filled for a named patient by a state-licensed pharmacy, is a different route. It does not make the drug approved or shown to work. It does mean a licensed pharmacist prepared it, a physician reviewed your history, and someone is accountable for follow-up. Compounded products also differ between pharmacies.

Sport

Drug testing and WADA

FDA’s briefing document states that BPC-157 is on the World Anti-Doping Agency’s prohibited list under the non-approved substances class, which is banned at all times. A prescription does not change that. If you compete in a tested sport, including many collegiate, military and masters events, check your governing body’s current list before any decision, and tell your physician first.

Regulatory status

BPC-157 and pharmacies: the timeline

BPC-157 is not an FDA-approved drug. For years it sat in a gray zone: pharmacies could compound only substances that met certain rules, and FDA had not placed it on the list of bulk substances they may use. The key dates are below.

• July 23, 2026. FDA’s Pharmacy Compounding Advisory Committee voted 8 for, 6 against and 1 abstaining on adding BPC-157 to the 503A bulks list. The vote is advisory and not binding. FDA review staff had proposed against adding it, citing a lack of quality data on safety and effectiveness.
• October 28, 2026. The U.S. Department of Health and Human Services, FDA’s parent department, announced its ‘Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances,’ covering six peptides, BPC-157 among them. The Federal Register notice was filed on October 28 and published on October 30, where the policy is described as a draft open to comment for two weeks. The National Community Pharmacists Association reported it on October 29. No end date was given.
• Still pending. Formal rulemaking to decide whether BPC-157 joins the 503A bulks list has not happened. That process is separate and usually takes a long time.

In plain terms, FDA currently allows licensed 503A pharmacies to prepare BPC-157 for an individual patient under a prescription. That is a decision not to take enforcement action, not an approval. The policy creates no rights, is not binding, and HHS has said it may revisit it, for example if a safety signal or a product quality problem appears. It applies only when ten conditions in its full text are met. Among them: the substance is the acetate form from an FDA-registered manufacturer, with a certificate of analysis for the lot; the product has one active ingredient; the label says “This is a compounded drug product. Not for resale.”; serious side effects and quality problems are reported to FDA’s MedWatch; the only device packaged with it is an FDA-cleared syringe; and an oral form needs documentation that it is absorbed adequately in humans. For BPC-157 the policy names the acetate form as a subcutaneous, intramuscular, oral or topical product.

Summit’s role

What Summit does with BPC-157

Dr. Miranda decides whether BPC-157 fits you after your history and labs. If he does decide it is reasonable, an independent, state-licensed pharmacy prepares it for you as a named patient. Summit does not dispense or sell it, and it keeps no stock in the office.

Nothing on this page promises a prescription. Given how little is known, Dr. Miranda may recommend a better-studied option first, or tell you plainly that waiting for more evidence makes sense. Individual results vary. See pricing for what the program includes, including labs.

Keep reading

Related medications

Sources

Where this comes from

All retrieved November 10, 2026.

1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and B. Federal Register FR Doc 2026-22192, October 30, 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
2. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg 2026. https://pubmed.ncbi.nlm.nih.gov/42885452/
3. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
4. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
5. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021. https://pubmed.ncbi.nlm.nih.gov/34324435/
6. FDA. Pharmacy Compounding Advisory Committee briefing document on BPC-157-related bulk drug substances, July 23, 2026. https://www.fda.gov/media/193343/download
7. FDA. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
8. HHS. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register, October 30, 2026. https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
9. NCPA. FDA grants enforcement discretion to compounding six peptides. October 29, 2026. https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides